Patient and donor characteristics for 3 transfusions preceding detection of Rh antibody specificities in individuals with SCD
| UPID . | Specificity . | RH haplotypes (presumed) . | Patient predicted Rh phenotype . | Donor unit phenotypes . | Units from Black donors . | |
|---|---|---|---|---|---|---|
| S 93 | anti-e | RHD-Ce | RHD-ce(733G) | D+ C+ cP E− e+ | 6e+, 0e− | 5 of 6 |
| S 108 | anti-e | DAU0-ce(48C) | Inactive RHD Ψ-ce(48C) | DA C− cA E− eA hrS+ | 4e+, 2e− | 4 of 6 |
| anti-hrS–like | Not typed for hrS | 0 of 7 (e− units) | ||||
| S 148 | anti-C†* | Weak partial 4.0-ce | Weak partial 4.0-ce(48C,733G) | DP C− c+ E− e+ | 0C+, 3C− | 3 of 3 |
| anti-e* | 3e+, 0e− | 3 of 3 | ||||
| S 159 | anti-E† | RHD-ce | DeletedD-ce(733G) | D+ C− c+ E− e+ | 0E+, 3E− | 3 of 3 |
| S 180 | anti-C† | RHD-ce(48C,733G) | DAU0-ce(48C) | D+ C− cA E− eA | 0C+, 4C− | 1 of 4 (Jsa− units) |
| S 205 | anti-D | Weak partial 4.0-ce(48C) | Inactive RHD Ψ-ce | DP C− c+ E− e+ | 4D+, 0D− | 3 of 4 |
| S 348 | anti-C† | RHD-ce(733G) | Weak partial 4.0-ce(48C,733G) | D+ C− cP E− eP fP | 0C+, 3C− | 1 of 3 |
| anti-e | 3e+, 0e− | 3 of 3 | ||||
| anti-E | 1E+, 2E− | 2 of 3 | ||||
| anti-f | Not typed for f | 2 of 6 | ||||
| S 425 | anti-e | RHD-cE | RHD-ce(733G) | D+ C- c+ E+ eP | 3e+, 0e− | 3 of 3 |
| S 450 | anti-D* | RHD-ce(733G) | DAU0-ce | D+ C- c+ E- e+ | 3D+, 0D− | 2 of 3 1 unknown |
| anti-C†* | 0C+, 3C− | 2 of 3 1 unknown | ||||
| S 775 | anti-e | RHD-cE | DIVa-ceTI | D+ C- c+ E- eP | 1e+, 2e− | 1 of 3 |
| anti-C† | 0C+, 6C− | 0 of 6 (e− units) | ||||
| S 1007 | anti-C† | RHD-ce(48C,733G) | RHD-ce | D+ C- c+ E- e+ | 0C+, 6C− | 4 of 6 |
| UPID . | Specificity . | RH haplotypes (presumed) . | Patient predicted Rh phenotype . | Donor unit phenotypes . | Units from Black donors . | |
|---|---|---|---|---|---|---|
| S 93 | anti-e | RHD-Ce | RHD-ce(733G) | D+ C+ cP E− e+ | 6e+, 0e− | 5 of 6 |
| S 108 | anti-e | DAU0-ce(48C) | Inactive RHD Ψ-ce(48C) | DA C− cA E− eA hrS+ | 4e+, 2e− | 4 of 6 |
| anti-hrS–like | Not typed for hrS | 0 of 7 (e− units) | ||||
| S 148 | anti-C†* | Weak partial 4.0-ce | Weak partial 4.0-ce(48C,733G) | DP C− c+ E− e+ | 0C+, 3C− | 3 of 3 |
| anti-e* | 3e+, 0e− | 3 of 3 | ||||
| S 159 | anti-E† | RHD-ce | DeletedD-ce(733G) | D+ C− c+ E− e+ | 0E+, 3E− | 3 of 3 |
| S 180 | anti-C† | RHD-ce(48C,733G) | DAU0-ce(48C) | D+ C− cA E− eA | 0C+, 4C− | 1 of 4 (Jsa− units) |
| S 205 | anti-D | Weak partial 4.0-ce(48C) | Inactive RHD Ψ-ce | DP C− c+ E− e+ | 4D+, 0D− | 3 of 4 |
| S 348 | anti-C† | RHD-ce(733G) | Weak partial 4.0-ce(48C,733G) | D+ C− cP E− eP fP | 0C+, 3C− | 1 of 3 |
| anti-e | 3e+, 0e− | 3 of 3 | ||||
| anti-E | 1E+, 2E− | 2 of 3 | ||||
| anti-f | Not typed for f | 2 of 6 | ||||
| S 425 | anti-e | RHD-cE | RHD-ce(733G) | D+ C- c+ E+ eP | 3e+, 0e− | 3 of 3 |
| S 450 | anti-D* | RHD-ce(733G) | DAU0-ce | D+ C- c+ E- e+ | 3D+, 0D− | 2 of 3 1 unknown |
| anti-C†* | 0C+, 3C− | 2 of 3 1 unknown | ||||
| S 775 | anti-e | RHD-cE | DIVa-ceTI | D+ C- c+ E- eP | 1e+, 2e− | 1 of 3 |
| anti-C† | 0C+, 6C− | 0 of 6 (e− units) | ||||
| S 1007 | anti-C† | RHD-ce(48C,733G) | RHD-ce | D+ C- c+ E- e+ | 0C+, 6C− | 4 of 6 |
Patient Rh antigen phenotype was predicted by RHD and RHCE genotype. Partial (P) antigens predicted from genotypes with variant alleles that result in Rh epitope(s) missing and absence of conventional antigen. Altered (A) predicted for patients with RHD*DAU0 or RHCE*ce48C and no conventional allele in trans as these 2 alleles have not been shown to lack epitopes. Antibody specificities in bold are potentially explained by patient’s RH genotype. Antibodies listed in order of identification for patients with multiple specificities: UPID S108 anti-e 12/2009, -hrS-like 3/2010; S148 anti-C and -e 5/2007; S348 anti-C 8/2004, -e 7/2005, -E 9/2005, -f 4/2014; S450 anti-D and -C 5/2005; S205 anti-C 8/2004, -D 7/2018, S775 anti-e 5/2013, -C 9/2014.
Two antibodies detected on the same date.
Denotes Rh specificities identified in antigen-negative patients who received antigen-negative units.